FDA removes clinical hold on Greenwich LifeSciences' Flamingo-01 Phase III trial

Greenwich LifeSciences, Inc.

FDA formally removed the clinical hold on July 11, 2022, allowing the Flamingo-01 Phase III trial to proceed.
Clinical hold was related to manufacturing and pharmacy process issues; company has addressed them with additional testing commitments.
Company has begun site initiation visits and will provide future updates on trial progress.
GLSI-100 is the drug candidate under development for breast cancer immunotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.